Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Open-Label Extension Study of TPIP in PH-ILD
NCT07234032Phase 3Recruiting
- Sponsor
- Insmed Incorporated
- Start
- Jul 2026
- Primary completion
- Jan 2031
- Modality
- Inhalation Devices, Prodrugs/Conditional Activator Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of treprostinil palmitil in Pulmonary Hypertension Due To Interstitial Lung Disease (PH-ILD), sponsored by Insmed Incorporated. Started Jul 2026; status: recruiting.
02
Drugs
treprostinil palmitil
03
Conditions
Pulmonary Hypertension Due To Interstitial Lung Disease (PH-ILD)
Beyond the preview
Go deeper on NCT07234032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07234032.